The systemic availability of buprenorphine administered by nasal spray

Authors:
Publisher website
Google Scholar
Abstract
— The kinetics and systemic bioavailability of intranasally administered buprenorphine have been investigated in 9 healthy volunteers in an intranasal/intravenous cross‐over study. Each subject received a nominal 0·3 mg dose of buprenorphine intranasally followed one week later by a matched dose intravenously. For the intranasal administration mean tmax and mean Cmax were 30·6 min and 1·77 ng mL−1, respectively. Mean intranasal bioavailability was 48·2 ± 8·3% (mean ± s.e.m.) of the intravenous value. Intranasal administration may represent a valuable new delivery route for buprenorphine.

This publication has 6 references indexed in Scilit: